دورية أكاديمية
Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy.
| العنوان: | Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. |
|---|---|
| المؤلفون: | Lyons YA; Departments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pradeep S; Departments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wu SY; Departments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Haemmerle M; Departments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hansen JM; Departments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wagner MJ; Departments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Villar-Prados A; Departments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nagaraja AS; Departments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dood RL; Departments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Previs RA; Departments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hu W; Departments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhao Y; Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mak DH; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Xiao Z; Department of Melanoma Medical Oncology-Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Melendez BD; Department of Melanoma Medical Oncology-Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lizee GA; Department of Melanoma Medical Oncology-Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mercado-Uribe I; Department of Pathology, Division of Pathology and Laboratory Medicine, Section of Gynecologic Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Baggerly KA; Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hwu P; Department of Melanoma Medical Oncology-Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Liu J; Department of Pathology, Division of Pathology and Laboratory Medicine, Section of Gynecologic Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Overwijk WW; Department of Melanoma Medical Oncology-Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Coleman RL; Departments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sood AK; Departments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for RNAi and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. |
| المصدر: | Oncotarget [Oncotarget] 2017 Aug 24; Vol. 8 (57), pp. 96496-96505. Date of Electronic Publication: 2017 Aug 24 (Print Publication: 2017). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Albany, N.Y. : Impact Journals |
| مستخلص: | Anti-angiogenesis therapy has shown clinical benefit in patients with high-grade serous ovarian cancer (HGSC), but adaptive resistance rapidly emerges. Thus, approaches to overcome such resistance are needed. We developed the setting of adaptive resistance to anti-VEGF therapy, and performed a series of in vivo experiments in both immune competent and nude mouse models. Given the pro-angiogenic properties of tumor-associated macrophages (TAMs) and the dominant role of CSF1R in macrophage function, we added CSF1R inhibitors following emergence of adaptive resistance to anti-VEGF antibody. Mice treated with a CSF1R inhibitor (AC708) after anti-VEGF antibody resistance had little to no measurable tumor burden upon completion of the experiment while those that did not receive a CSF1R inhibitor still had abundant tumor. To mimic clinically used regimens, mice were also treated with anti-VEGF antibody and paclitaxel until resistance emerged, and then a CSF1R inhibitor was added. The addition of a CSF1R inhibitor restored response to anti-angiogenesis therapy, resulting in 83% lower tumor burden compared to treatment with anti-VEGF antibody and paclitaxel alone. Collectively, our data demonstrate that the addition of a CSF1R inhibitor to anti-VEGF therapy and taxane chemotherapy results in robust anti-tumor effects. Competing Interests: CONFLICTS OF INTEREST RLC serves on the advisory board and as a consultant for Genentech/Roche. |
| References: | Cytometry A. 2015 Apr;87(4):346-56. (PMID: 25598437) J Clin Oncol. 2014 May 1;32(13):1302-8. (PMID: 24637997) J Ovarian Res. 2014 Feb 08;7:19. (PMID: 24507759) Nat Rev Cancer. 2008 Aug;8(8):592-603. (PMID: 18650835) Invest New Drugs. 2013 Jun;31(3):760-8. (PMID: 22907596) Drug Resist Updat. 2009 Jun;12(3):74-80. (PMID: 19394890) Immunotherapy. 2013 Oct;5(10):1075-87. (PMID: 24088077) Cancer Cell. 2014 Jun 16;25(6):846-59. (PMID: 24898549) N Engl J Med. 2011 Dec 29;365(26):2473-83. (PMID: 22204724) J Bone Miner Res. 2008 Jun;23(6):826-36. (PMID: 18558816) Crit Rev Oncol Hematol. 2015 Jun;94(3):279-90. (PMID: 25794812) Cell Rep. 2015 Apr 28;11(4):577-91. (PMID: 25892230) Lancet Oncol. 2015 Aug;16(8):949-56. (PMID: 26179200) NPJ Breast Cancer. 2016;2:null. (PMID: 26998515) |
| معلومات مُعتمدة: | T32 CA009666 United States CA NCI NIH HHS; T32 CA101642 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: CSF1R inhibition; adaptive resistance; anti-VEGF therapy; tumor associated macrophages; tumor microenvironment |
| تواريخ الأحداث: | Date Created: 20171213 Latest Revision: 20200504 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC5722500 |
| DOI: | 10.18632/oncotarget.20410 |
| PMID: | 29228548 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1949-2553 |
|---|---|
| DOI: | 10.18632/oncotarget.20410 |